> 
**Exhibit 99.1**

 

| For immediate release: | Media Contact:    |
|------------------------|-------------------|
| September 2, 2009      | Chris Loder       |
|                   | (212) 733-7897    |
|                   | Investor Contact: |
|                   | Suzanne Harnett   |
|                   | (212) 733-8009    |

> 
** **

**Pfizer Concludes Previously Disclosed Settlement Agreement With U.S.  Department Of Justice Regarding Past Promotional Practices**      ---***Company Reaches Settlement with States on Related Matter***

NEW YORK, NY, September 2 – Pfizer Inc today announced that it has finalized a  previously reported agreement in principle with the U.S. Department of Justice  (DOJ) to settle an investigation regarding past off-label promotional practices  related to Bextra, which Pfizer voluntarily withdrew from the market in  2005.  The final agreement also resolves  other DOJ investigations involving alleged past off-label promotional practices  concerning Zyvox, Geodon and Lyrica, allegations related to certain payments to  healthcare professionals involving these and nine other Pfizer medicines, and  several related qui tam actions.  Pfizer  previously disclosed a related $2.3 billion charge to its fourth-quarter and  full-year 2008 earnings in connection with the DOJ agreement in principle on  January 26, 2009.  No additional charge  to the company’s earnings will be recorded in connection with this settlement.

In addition, the company  has reached agreements with attorneys general in 42 states and  the District of Columbia to  settle state civil consumer protection allegations related to its past  promotional practices concerning Geodon.  The company will pay a total of  $33 million to the settling states and will take a charge in that amount to  third-quarter 2009 earnings.

“These  agreements bring final closure to significant legal matters and help to enhance  our focus on what we do best – discovering, developing and delivering innovative  medicines to treat patients dealing with some of the world’s most debilitating  diseases,” said Amy W. Schulman, senior  vice president and general counsel of Pfizer.   “We regret certain actions taken in the past, but are proud of the action  we’ve taken to strengthen our internal controls and pioneer new procedures so  that we not only comply with state and federal laws, but also meet  the high standards that patients, physicians and the public expect from a  leading worldwide company dedicated to healing and better health.  Corporate integrity is an absolute priority for  Pfizer,  and we will continue to take appropriate actions to further enhance our  compliance practices and strengthen public trust in our company.” 

Under  the agreement with the DOJ, Pfizer will pay a previously disclosed total of  $2.3 billion ($1.0 billion in civil payments related to a number of medicines,  and a $1.3 billion criminal penalty related only to Bextra), and a Pfizer  subsidiary, Pharmacia & Upjohn Company, Inc., will plead guilty to one  criminal count of violating the U.S. Food, Drug, and Cosmetic Act related to  its past promotion of Bextra.  A portion  of the civil payments will be distributed to 49 states and the District of Columbia  pursuant to agreements with each state’s Medicaid division.  

The terms of the DOJ settlement  require Pfizer to pay approximately $503 million to resolve civil allegations  concerning past promotional practices related to Bextra.  In addition, the  company will make payments to resolve other civil allegations involving past  promotional practices as follows:  approximately $301 million for Geodon,  approximately $98 million for Zyvox, and approximately $50 million for  Lyrica.  The settlement also includes a civil payment of approximately $48  million to resolve allegations relating to certain payments to healthcare  professionals involving nine other Pfizer medicines. 

Pfizer  expressly denies all of these civil allegations, with the exception that Pfizer  acknowledges certain improper actions related to the promotion of Zyvox.

As  part of the DOJ settlement, Pfizer has entered into a Corporate Integrity  Agreement (CIA) with the Office of Inspector General (OIG) of the U.S.  Department of Health and Human Services (HHS).   The CIA institutes certain new measures and requires Pfizer to continue  maintenance of a corporate compliance program for a period of five years. 

Pfizer’s  existing compliance program includes a dedicated chief compliance officer,  corporate compliance committee, code of conduct, extensive compliance training,  policies and procedures regarding the appropriate promotion of Pfizer’s  products, auditing and monitoring, a compliance hotline and extensive  procedures to investigate and remediate potential issues of non-compliance with  company policy or applicable legal requirements.  Pursuant to the CIA, Pfizer will engage an  Independent Review Organization (IRO) that will help the company assess and  evaluate its promotional and product-related business functions.           The  CIA memorializes additional voluntary initiatives that reflect the company’s  efforts toward greater transparency such as Pfizer’s plan, announced in  February 2009, to disclose publicly its financial relationships with  physicians, medical organizations and patient advocacy groups, including  investigators who conduct clinical research.  Pfizer is the first biopharmaceutical  company to commit to reporting payments for conducting Phase I-IV clinical  trials in addition to disclosing payments for speaking and consulting.  Although Pfizer was subject to a prior CIA,  it has consistently and voluntarily strengthened its compliance program beyond  those requirements, including enhancements to the company’s comprehensive  product risk assessment and mitigation process and compliance monitoring  operations. 

**Pfizer  Inc: Working together for a healthier worldTM**      Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new  approaches to better health.  We  discover, develop, manufacture and deliver quality, safe and effective  prescription medicines to treat and help prevent disease for both people and  animals.  We also partner with healthcare  providers, governments and local communities around the world to expand access  to our medicines and to provide better quality health care and health system  support.  At Pfizer, colleagues in more  than 90 countries work every day to help people stay happier and healthier  longer and to reduce the human and economic burden of disease worldwide.